Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0700

+1.4%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Howard Williams	11/6/2012 7:46:29 AM
	of 13111

Provectus presents PV-10 nonclinical data Tuesday November 6, 2012 In a news article entitled "Provectus presents PV-10 nonclinical data", Pharmaceutical Business Reviewreported on data from a nonclinical study investigating PV-10's bystander effect using hepatocellular carcinoma (HCC) and melanoma tumors in immunocompetent and immunodeficient mice. The data were recently presented at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting. The article is available on the PBR website at the following link: http://clinicaltrials.pharmaceutical-business-review.com/news/provectus-presents-pv-10-nonclinical-data-301012

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next